ArticleCureus2025
Correlation Between Fibroblast Growth Factor 23 and Biochemical Parameters in Hemodialysis Patients With End-Stage Renal Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibroblast growth factor 23 (FGF-23) is one of the biomarkers that plays a role in regulating phosphate (P) levels in hemodialysis (HD) patients with end-stage renal disease (ESRD). In addition to FGF-23, intact parathyroid hormone (iPTH) and homocysteine (Hcy) also play a role in the chronic kidney disease (CKD)-related mineral bone disease (MBD) process. In this study, we evaluated the correlation of glomerular filtration rate (GFR), serum creatinine, calcium, and phosphorus levels with FGF-23, iPTH, and Hcy. These parameter values may guide us for new prognostic and treatment definition targets in HD patients with ESRD.
methodsWe retrospectively evaluated serum FGF-23, Hcy, and iPTH concentrations in 103 HD patients with ESRD. Biochemical laboratory parameter data were analyzed to determine the correlation between GFR, blood creatinine, phosphorus, and calcium levels. The inclusion criteria for this study were patients with chronic kidney disease who were undergoing HD and did not have primary cardiovascular disorders. The exclusion criteria included patients with primary cardiovascular disease undergoing HD; patients with acute renal failure; patients with acute cardiovascular failure, and patients with other pathologies undergoing HD (e.g. autoimmune and oncological diseases, patients who had undergone surgery within the last two months). Color Doppler Echocardiography and Electrocardiogram (ECG) were performed to all HD patients for cardiac evaluation. Before HD blood samples were collected and the centrifugation method was used for serum fluid collection. We used the ELISA method to record demographic data and biochemical laboratory parameter results for all patients.
resultsIn 103 cases of HD patients, 65 were male (63.1%) and 38 were female (36.9%). The mean ± SD parameter result for age was 64±13.64. The detailed baseline information for biochemical laboratory parameters, including Hg, CRP, glucose, creatinine, GFR, K, Na, Ca, P, ALT, AST, iPTH, Hcy, and FGF-23, were evaluated. FGF-23 levels were positively correlated with serum P (r=0.78, p=0.01), iPTH (r=0.61, p=0.01), and creatinine (r=0.78, p=0.01) and negatively with GFR (r=-0.64, p=0.01). FGF-23 and Hcy showed a positive linear correlation (r=0.65, p=0.01). No statistically significant correlation was found with Ca values (r=-0.12, p>0.05). Conclusion: There is no single biomarker that can completely predict CKD progression and follow-up. Changes in FGF-23, iPTH, and Hcy levels together and correlation with other biochemical laboratory parameters may be the earliest markers for HD patients. These parameter values together can be used to guide strategies for the prognostic issues and early treatment management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.